Transasia Bio-Medicals was founded in 1979 by Mr. Suresh Vazirani who recognized the need for dedicated healthcare solutions for developing nations after witnessing the short comings of the healthcare systems in his home country India.
He quickly identified the need for quality, affordable diagnosis in low income groups that could not afford expensive treatments for cure. In developing nations with exponentially growing populations and limited means to tackle challenges on multiple fronts, resources dedicated to prevent and hinder disease result in a greater impact rather than those focusing on the more costly, risky and lengthy treatments for cure.
After partnering with multiple diagnostics companies from around the world to service this need, he found that their products were unable to make a significant impact in these inadequately developed environments. Their products were not suited to a highly fragmented, price-sensitive market with poor infrastructure and expertise.
Committed to find a solution, in 1995 he started Erba Mannheim, Germany with the vision to make world class European technology accessible to emerging markets. He combined it with efficient, low cost manufacturing and unparalleled market expertise to create the first fully integrated In-vitro Diagnostics company dedicated to fulfilling the needs of the emerging market customers.
Transasia Bio-Medicals is established to address the needs of the Indian market by partnering with international IVD companies.
Transasia’s R&D Centre and a production facility are setup to provide indigenously manufactured instruments. The first analyzer is launched.
Transasia partners with Sysmex Corporation, Japan, to bring world class hematology automation to India
Enters the European market, having received the CE certification. Becomes the first Indian company to exhibit at AACC (USA) & Medica (Germany), the two top global healthcare exhibitions.
Going beyond clinical chemistry and hematology, Transasia expands into the immunoassay segment by developing its first products in Blood Banking and Infectious Diseases testing.
Establishes Erba Mannheim in Germany and develops its first fully automated clinical chemistry analyzer.
Transasia crosses the Rs. 1 billion mark to become India’s largest IVD Company.
Erba strengthens its portfolio by offering products in Urinalysis, through its first acquisition - Pliva Lachema Diagnostika, Czech Republic.
Forays into the Autoimmunity and Hormones segment by acquiring a majority stake in IVAX Diagnostics Inc., USA.
Acquires Diasis Diagnostik Systems headquartered in Istanbul, Turkey.
Enters the diabetes testing segment with the acquisition of Drew Scientific, USA and JAS Diagnostic, USA and further goes on to acquire Maxmat, France to cater to the Hemostasis (Coagulation) segment.
Ventures into molecular diagnostics with the acquisition of Lumora, UK.
Acquires Calbiotech Group of Companies, USA to strengthen its foray into Immunoassay.